Comparative analysis of adverse event profiles for CAR-T cell therapies and bispecific antibodies in lymphoma.

• DOI: 10.1200/jco.2025.43.16_suppl.e19019
• Publication Date: 2025-05-28T13:33:39Z
• Authors: Majid Jaberi-Douraki; Shahzad Raza; Xuan Xu; Remya Ampadi Rama...; Mobina Golmohammadi; Hossein Sholehrasa; Jim Riviere; Deepa Jagadeesh
• Keywords: Bispecific antibody

e19019 Background: CAR-T cell therapies and bispecific antibodies (BsAbs) emerged as transformative treatment options for relapsed or refractory lymphomas. Despite their efficacy, these come with distinct safety profiles. modify the patient's T-cells to target tumor cells, while BsAbs engage both cells. This study compares adverse event (AE) profiles of BsAb in lymphoma treatment. Methods: A retrospective analysis was conducted using FAERS database assess AE reports associated (Breyanzi, Kymriah, Yescarta, Tecartus) (Epcoritamab, Glofitamab, Odronextamab, Mosunetuzumab, Plamotamab). AEs were categorized by System Organ Classes (SOCs) MedDRA terminology, frequency events calculated each drug. Results: total 114,398 analyzed: Yescarta (44,620), Kymriah (35,135), Tecartus (15,043), Epcoritamab (9,927), Glofitamab (4,373), Breyanzi (2,929), Mosunetuzumab (2,344), Odronextamab (22), Plamotamab (5). For therapies, most frequently reported nervous system (15.33%), General (11.23%), immune (9.59%). In contrast, had higher incidences related Infections (11.96%), (11.80%), Immune (8.28%). showed an increased incidence psychiatric disorders, more commonly infection-related AEs. Notably, disorders prevalent across therapeutic modalities. The results are summarized table below. Conclusions: highlights key differences lymphoma. a neurological AEs, demonstrated greater risk infections. These findings may offer valuable guidance clinicians therapy selection underscore importance vigilant monitoring, particularly toxicities treatments risks BsAbs. Further research is recommended better understand trends inform improved management strategies options. AE* % Nerv 15 5 4 10 9 - 16 Genrl 11 12 17 64 20 13 Immun 8 7 40 Infec 6 14 Resp Blood Inv Musc 2 3 Neopl Vasc Card Metab Skin Surg 1 0 * Nerv: Nervous system;Card: Cardiac; Genrl: disorders; Immun: system; Infec: Infections; Inv: Investigations; Metab: Metabolism; Musc: Musculoskeletal; Neopl: Neoplasms;Resp: Respiratory; Surg: Surgical medical procedures; Vasc: Vascular.